| Max N Wiznitzer, MD | |
|
11100 Euclid Ave, Cleveland, OH 44106-1716 | |
| (216) 844-7700 | |
| (216) 286-6341 |
| Full Name | Max N Wiznitzer |
|---|---|
| Gender | Male |
| Speciality | Pediatric Medicine |
| Experience | 47 Years |
| Location | 11100 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033136015 | NPI | - | NPPES |
| 000000526174 | Other | OH | ANTHEM |
| 0013055270003 | Medicaid | PA | |
| 000000028264 | Other | OH | ANTHEM |
| P00445001 | Other | OH | RAILROAD MEDICARE |
| 0631598 | Other | OH | BCMH |
| 0631598 | Medicaid | OH | |
| 731878 | Other | OH | BUCKEYE |
| 000000221332 | Other | OH | UNISON |
| 0640754 | Other | OH | AETNA |
| 1033136015 | Medicaid | MI | |
| 364144 | Other | OH | WELLCARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0402X | Psychiatry & Neurology - Neurology With Special Qualifications In Child Neurology | 35-043073 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Parma Community General Hospital | Parma, OH | Hospital |
| University Hospitals Ahuja Medical Center | Beachwood, OH | Hospital |
| University Hospitals Of Cleveland | Cleveland, OH | Hospital |
| University Hospitals - Elyria Medical Center | Elyria, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Hospitals Medical Group Inc | 4789682493 | 1466 |
News Archive
Fifty-eight percent of U.S. physicians who don't use electronic medical records (EMRs) intend to purchase an EMR system within the next two years, according to a new report from Accenture.
The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate, and caffeine, on chess play is being published in the March edition of the peer-reviewed journal European Neuropsychopharmacology.
Cancer is a leading cause of death worldwide. Our evolutionary struggle with this disease is the focus of a free, public lecture at UC Riverside.
Tenet Healthcare Corporation today reported adjusted EBITDA of $203 million for the quarter ended September 30, 2010, a decrease of $37 million, or 15.4 percent, compared to $240 million for the third quarter of 2009. Net income attributable to common shareholders for the third quarter of 2010 was $932 million, or $1.68 per diluted share, compared to a net loss of $3 million, or $0.01 per diluted share, for the third quarter of 2009.
Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
› Verified 9 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
Fifty-eight percent of U.S. physicians who don't use electronic medical records (EMRs) intend to purchase an EMR system within the next two years, according to a new report from Accenture.
The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate, and caffeine, on chess play is being published in the March edition of the peer-reviewed journal European Neuropsychopharmacology.
Cancer is a leading cause of death worldwide. Our evolutionary struggle with this disease is the focus of a free, public lecture at UC Riverside.
Tenet Healthcare Corporation today reported adjusted EBITDA of $203 million for the quarter ended September 30, 2010, a decrease of $37 million, or 15.4 percent, compared to $240 million for the third quarter of 2009. Net income attributable to common shareholders for the third quarter of 2010 was $932 million, or $1.68 per diluted share, compared to a net loss of $3 million, or $0.01 per diluted share, for the third quarter of 2009.
Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Max N Wiznitzer, MD 3605 Warrensville Center Rd, Shaker Hts, OH 44122-5203 Ph: (216) 286-6295 | Max N Wiznitzer, MD 11100 Euclid Ave, Cleveland, OH 44106-1716 Ph: (216) 844-7700 |
News Archive
Fifty-eight percent of U.S. physicians who don't use electronic medical records (EMRs) intend to purchase an EMR system within the next two years, according to a new report from Accenture.
The first study to both show and measure the effects of cognitive-enhancing drugs such as modafinil, methylphenidate, and caffeine, on chess play is being published in the March edition of the peer-reviewed journal European Neuropsychopharmacology.
Cancer is a leading cause of death worldwide. Our evolutionary struggle with this disease is the focus of a free, public lecture at UC Riverside.
Tenet Healthcare Corporation today reported adjusted EBITDA of $203 million for the quarter ended September 30, 2010, a decrease of $37 million, or 15.4 percent, compared to $240 million for the third quarter of 2009. Net income attributable to common shareholders for the third quarter of 2010 was $932 million, or $1.68 per diluted share, compared to a net loss of $3 million, or $0.01 per diluted share, for the third quarter of 2009.
Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.
› Verified 9 days ago
Mr. Apisit Boongird, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12000 Fairhill Rd Apt 813, Cleveland, OH 44120 Phone: 216-526-2014 | |
Rachel Sieke, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, None, Cleveland, OH 44195 Phone: 717-880-7438 | |
Keming Gao, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-2400 | |
Richard J Lederman, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 800-223-2273 | |
Richard C Burgess, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Suite S-51, Cleveland, OH 44195 Phone: 800-223-2273 | |
Joseph Michael Austerman, D. O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-2200 Fax: 216-444-9054 | |
Robert J Marquardt, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-2200 Fax: 216-445-9908 |